{
  "id": 15495354,
  "title": "Disc Medicine to present Phase 3 trial results for bitopertin",
  "url": "https://urgent.news/2026/10/18/disc-medicine-to-present-phase-3-trial-results-for-bitopertin",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-18T21:04:28.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/disc-medicine-to-present-phase-3-trial-results-for-bitopertin-93CH-4956077"
  },
  "original_language": "en",
  "account": "WATERTOWN, Mass. - On October 19, 2026, Disc Medicine Inc. will hold a webcast to share the major findings from its APOLLO Phase 3 trial evaluating bitopertin for the treatment of erythropoietic protoporphyria. The event begins at 8:00 a.m. ET. A recorded version of the presentation will be posted on the company's website afterwards. Bitopertin is a drug being developed to inhibit glycine transporter 1, aiming to alter heme biosynthesis. It is being investigated as a potential therapy for hematologic conditions, particularly erythropoietic porphyrias. Clinical studies, including the Phase 2 BEACON and AURORA trials, as well as the open-label HELIOS extension trial and the current Phase 3 APOLLO trial, have examined bitopertin's effectiveness in patients with erythropoietic protoporphyria. Disc Medicine secured global licensing rights to bitopertin from Roche in May 2021. The Watertown-based company specializes in creating therapies for hematologic diseases by targeting heme biosynthesis and iron regulation.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}